Among the NuRD-associated proteins, only RBBP4 weakly interacted with the general P-TEFb activator BRD4[40](Figures 1D,S1G)

Among the NuRD-associated proteins, only RBBP4 weakly interacted with the general P-TEFb activator BRD4[40](Figures 1D,S1G). activator, to CDK9. We show that an IKAROS mutant that is unable to bind PP1 cannot sustain gene expression and impedes normal differentiation of IkNULLhematopoietic progenitors. Finally, the knock-down of the NuRD subunit Mi2 (S)-crizotinib reveals that this occupancy of the NuRD complex at transcribed regions of genes favors the relief of POL II promoter-proximal pausing and thereby, promotes transcription elongation. == Author Summary == Perturbation of the expression level of IKAROS, a transcription factor crucial during hematopoiesis, is usually associated with malignant transformation in mice and humans. The importance of IKAROS expression levels for the control of target-gene regulation was resolved in hematopoietic progenitor cells. The collaboration between IKAROS and the Nucleosome Remodeling and Deacetylase (NuRD) complex can promote gene activation or repression. IKAROS can also interact with the Positive-Transcription Elongation Factor b (P-TEFb) and the Protein Phosphatase 1 (PP1), an important P-TEFb regulator. Immunoaffinity purification of IKAROS interacting proteins and Fast Protein Liquid Chromatography analysis revealed a dynamic conversation between IKAROS, PP1 and the newly defined NuRD-P-TEFb complex. This complex can be targeted to specific genes in cells expressing high levels of IKAROS to promote productive transcription elongation. Based on our results we suggest that, in addition to P-TEFb, the NuRD complex and PP1 are required to facilitate transcription elongation (S)-crizotinib of IKAROS-target genes and normal differentiation of hematopoietic progenitor cells. == Introduction == The tumor suppressor IKAROS is usually a transcription factor critical for hematopoietic multi-lineage priming, cell fate and lineage determination[1][5]. Mice homozygote for theIkarosnull mutation (IkNULL) display severe defects in lymphocyte development and function, and develop leukemias and lymphomas with complete penetrance[6]. These phenotypes reflect the requirement of IKAROS to activate the lymphoid program in hematopoietic progenitor cells (HPCs)[4]. IKAROS is also involved in transcriptional regulation of erythroid- and myeloid-specific genes[7][13]. The hematopoietic differentiation is usually affected not only by the presence or absence of IKAROS, but also by its relative expression level[14]. In particular, during B-cell progenitor differentiation, dynamic change of IKAROS expression level has been identified as a key regulator for the expression of multiple target genes[15],[16]. CFD1 IKAROS controls chromatin organization mainly through association with the Nucleosome Remodeling and Deacetylase (NuRD) complex[5],[17],[18]. NuRD was initially identified as a repressive complex but it was exhibited afterwards to promote transcription of specific genes as well[5],[19][22]. It remains to be defined how this HDAC-containing complex activates transcription. IKAROS (S)-crizotinib contributes to the assembly and stability of the pre-initiation complex (PIC) at promoters[13],[23][26]and interacts directly with CDK9, the catalytic subunit of P-TEFb (Positive-Transcription Elongation Factor b)[27]. CDK9 phosphorylates the C-terminal domain name (CTD) of the large subunit of RNA Polymerase II (POL II) on Ser2 as well as the SPT5 subunit of DSIF and the E subunit of NELF. These events (S)-crizotinib are required to release promoter-proximal paused POL II and thus, allow productive transcription elongation. Most nuclear P-TEFb is usually sequestered in the 7SK snRNP repressive complex. This repressive complex is characterized by the snRNP molecule and the proteins HEXIM (HEXIM1 or 2), LARP7 and MePCE[28]. Of interest here, is the dissociation of the P-TEFb from this repressive complex promoted by the sequential activity of the protein (S)-crizotinib phosphatase 2B (PP2B) that favors conformation changes of the 7SK snRNP and protein phosphates 1 (PP1), involved in CDK9 dephosphorylation at different residues including Thr186 and Ser175[29],[30]. Dephosphorylated CDK9/P-TEFb is usually preferentially recruited to promoters by the general factor BRD4 or specific transcription factors such as HIV TAT[31][33]. Then, CDK9/P-TEFb becomes catalytically active and promotes the release of promoter-proximal paused POL II when it is re-phosphorylated by the TFIIH associated CDK7[30]. PP1 is one of the three catalytic subunits (, or ) which, together with a regulatory subunit, forms each PP1 enzyme[34]. Interestingly, IKAROS interacts with PP1 and is dephosphorylated by this phosphatase[35]. Whether the IKAROS-PP1 conversation is usually important for Cdk9/P-TEFb activation and thus, transcription elongation of IKAROS-target genes is not known. Here, we sought to define the importance of these protein associations for IKAROS and NuRD.